STAT+: FDA staff reiterate concerns about Replimune skin cancer treatment

Regulators at the FDA have reiterated concerns that Replimmune does not have adequate data to support an approval of its investigational skin cancer treatment.
💡 AI analysis provides alternative perspectives on current events